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Objective: Serum microRNAs (miRNAs) are a novel class of diagnostic and prognostic biomarkers for numerous
cancers. However, the level and clinical relevance of circulating miR-205 transcripts in human serum of cervical
cancer patients are unclear. The purpose of this study was to determine serum miR-205 levels in cervical cancer
patients and explore its association with clinicopathological factors and prognosis.
Methods: Serum miR-205 expression was investigated in 60 cervical cancer patients and 60 healthy normal controls
by using real-time PCR. Correlations between miR-205 expression and the clinicopathological features and prognosis
of cervical cancer patients were then evaluated. Receiver operating characteristic curves were used to evaluate the
sensitivity and specificity of serum miR-205.
Results: Serum miR-205 was significantly upregulated in cervical cancer patients compared with healthy donors
(p < 0.01), and a high level of miR-205 expression was correlated with poor tumor differentiation (p = 0.009), lymph
node metastasis (p = 0.015) and increased tumor stage (p = 0.001). The serum miR-205 level was capable of separating
advanced stage from early stage metastatic cervical cancer from non-metastatic samples and poorly differentiated
tumors from differentiated tumors with an area under the curve values of 0.74, 0.694 and 0.717, respectively. The
expression of miR-205 was also higher in the cervical cancer tissues compared with the para-carcinoma tissues. In
addition, Kaplan-Meier survival analysis showed that cervical cancer patients with high miR-205 expression tended to
have shorter overall survival. In multivariate Cox regression analysis, miR-205 was identified as an independent
prognostic marker.
Conclusions: Serum miR-205, which is upregulated in cervical cancer, represents a predictive biomarker for the
prognosis of cervical cancer patients.
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Cervical cancer, one the most commonly malignant tu-
mors, has become a major health problem for women
worldwide, particularly in developing countries [1,2].
Cervical cancer develops step-by-step and involves a se-
quential progression from normal cervical epithelium to
preneoplastic cervical intraepithelial neoplasia and then
to invasive cervical cancer [3]. Increasing evidences
showed that early detection by testing for high-risk human
papillomavirus (HPV) and cervical papilloma smears have* Correspondence: chenfang1006@sina.com
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unless otherwise stated.reduced cervical cancer mortality. However, these
methods do not detedted the development of cervical can-
cer directly [4]. Therefore, new and less invasive bio-
markers are needed to improve the detection and
prognostic outcome of cervical cancer.
MicroRNAs (miRNAs), small non-coding RNA mole-
cules, play a central role in post-transcriptional gene
regulation by binding to a target site in the 3’-UTR of
target mRNAs [5]. MiRNAs are involved in pathological
and physiological activities [6]. In recent years, the rela-
tionship between miRNA and cancer has become a re-
search focus. Tumor initiation and progression is related
to altered expression of miRNAs [7]. MiRNAs are not
only expressed in cancer tissues but also in sera [8,9].
Further investigation confirmed that circulating miRNAs. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Expression analysis of miR-205 in the serum of
cervical cancer patients. The expression of miR-205 in cervical
cancer patient serum was higher that in normal controls (P < 0.01).
Figure 2 The expression of miR-205 in cervical cancer tissues.
qPCR results showed that miR-205 expression was considerably
higher in the cervical cancer tissues compared with para-carcinoma
tissues (**P < 0.01).
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serum and plasma [10]. As a result, circulating miRNAs
have been exploited as a diagnostic tool for early cancer
detection, risk assessment and prognosis [11].
MiR-205 acts as an oncogene by modulating the ex-
pression of multiple cancer-related target genes [12]. In
addition, miR-205 is significantly overexpressed in hu-
man cervical cancer tissues and promotes proliferation
and migration of cervical cancer cells by targeting
CYR61 and CTGF [13]. Circulating miR-205 has been
reported as a biomarker for the detection and diagnosis
of lung cancer, particularly at its very early stage [14].
However, the clinical significance of circulating miR-205
levels in cervical cancer remains unclear. Thus, the aim
of this study was to evaluate whether serum miR-205
was capable of acting as a diagnostic and prognostic bio-
marker for cervical cancer patients. Here, we report that
serum miR-205 is upregulated in cervical cancer and
represents a predictive biomarker for the prognosis of
cervical cancer patients.
Results
Higher levels of miR-205 in the serum of cervical cancer
patients
MiR-205 expression was significantly higher in human
cervical cancer than in normal tissue, and it also pro-
motes cervical cancer cell proliferation and migration
[13]. Therefore, the level of miR-205 was determined in
the serum of the cervical cancer patients. The results
showed that among the 60 cervical cancer samples an-
alyzed, serum miR-205 was upregulated 5.74-fold in
cervical cancer patients compared with the level in
healthy donors. Summarized data from all individuals
indicated that the relative expression of miR-205 in
cervical cancer patients’ serum (1.18 ± 0.57) was signifi-
cantly higher than that in healthy donors’ serum (0.2 ±
0.12) (P < 0.01, Figure 1).
Higher expression of miR-205 in cervical cancer tissues
To further demonstrate the role of miR-205 in cervical
cancer, its expression was measured in cervical cancer
tissues. As shown in Figure 2, the miR-205 expression
was significantly increased (>3-fold higher) in cervical
cancer tissues (n = 3) compared with paracancerous tis-
sues (n = 3) (p < 0.01), which is consistent with an onco-
genic role of miR-205.
Correlation of clinicopathological features of cervical
cancer with circulating miR205
To better understand the potential roles of serum miR-
205 in cervical cancer development and progression, the
relationships between miR-205 and various clinical fea-
tures of cervical cancer were determined. In the present
study, the average fold change of miR-205 (miR-205 inserum of cervical cancer patient compared with healthy
donors) was 5.74-fold. The average fold change was used
as the threshold, and patients were separated into high
expression (above 5.74-fold) and low expression (below
5.74-fold) groups. As shown in Table 1, miR-205 expres-
sion was significantly higher in the serum of patients
with advanced FIGO stage cervical cancer than those
with early FIGO stage (P = 0.001, Table 1). The expres-
sion of miR-205 in lymph node metastasis-positive
patients was significantly increased compared to that in
lymph node metastasis-negative patients (P = 0.015,
Table 1). There was a tendency for less well differenti-
ated tumors to express higher levels of miR-205 (P =
0.009, Table 1). However, there was no correlation be-
tween miR-205 expression and other clinical features,
such as age and HPV infection.
Table 1 Correlation of clinicopathological features of










<50 28 15 13
≥50 32 15 17
Tumor size (cm)
<4 32 14 18 0.438
≥4 28 16 12
HPV 0.671
Positive 54 28 26





Poor differentiation 33 22 11
FIGO stage 0.001
Ib ~ IIa 26 6 20
IIb ~ IIIa 34 24 10
Lymph node metastasis 0.015
No 22 6 16
Yes 38 24 14
Figure 3 Kaplan-Meier survival curves of cervical cancer
patients. The 5-year overall survival rate of cervical cancer patients
with high serum miR-205 expression (16.67%) was significantly lower
than that of cervical cancer patients with low serum miR-205
expression (53.33%, P = 0.003).
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To further evaluate whether serum miR-205 levels were
associated with cervical cancer prognosis, we performed
survival analysis. The survival period of the patients was
defined as the duration from the time of surgery to
death, or to the last follow-up day. As shown in Figure 3,
cervical cancer patients with higher miR-205 expression
had significantly poorer survival than those with lower
expression of miR-205 (log-rank test: P = 0.003). The 5-
year overall survival rate in cervical cancer patients with
lower serum miR-205 expression was 53.33%, whereas
that of patients with higher miR-205 expression was
16.67%. To determine the possibility of serum miR-205
as an independent risk factor for poor prognosis, both
clinicopathological factors and the level of serum miR-
205 expression were evaluated by multivariate Cox re-
gression analysis. The results showed that lymph node
metastasis and high level of serum miR-205 were inde-
pendent factors to predict the overall survival of cervical
cancer patients (Table 2).
Capability of miR-205 to function as a biomarker for
cervical cancer prognosis
The specificity and sensitivity of miR-205 as a cervical
cancer prognosis biomarker was calculated by receiveroperating characteristic (ROC) curves. ROC analysis re-
vealed that miR-205 had a sensitivity of 76.5%, a specifi-
city of 73.1% and an area under the curve (AUC) of 0.74
(p = 0.002, Figure 4A) when comparing stages Ib ~ IIa
and stage IIb ~ IIIa. MiR-205 had an AUC of 0.694 with
a sensitivity of 71.1% and specificity of 72.7% (p = 0.013,
Figure 4B) for separation of metastatic cervical cancer
from non-metastatic samples. ROC curve analysis also
revealed that serum miR-205 was a valuable biomarker
to distinguish well to moderately differentiated from
poorly differentiation tumors, with a sensitivity of 76.5%,
a specificity of 73.1% and an AUC of 0.717 (p = 0.004,
Figure 4C). The cut-off value was 0.995 with the highest
specificity and sensitivity. Taken together, this analysis
revealed that serum miR-205 is a novel and efficient bio-
marker for cervical cancer prognosis.Discussion
Increasing evidence shows that serum miRNAs are
promising novel biomarkers for the diagnosis and prog-
nosis of cancer [8]. In this study, we first confirmed by
qPCR that miR-205 levels are significantly higher in the
serum of cervical cancer patients, and that a high level
of miR-205 expression correlated with poor tumor dif-
ferentiation, lymph node metastasis and increased tumor
stage. Notably, patients with high serum miR-205 levels
had a significantly lower survival rate than those with
low expression levels, and serum miR-205 was an inde-
pendent risk factor for poor prognosis. These results
suggested that serum miR-205 could be used as a poten-
tial predictor of prognosis in cervical cancer.
Table 2 Multivariate analysis for prognostic factors
Variate Subset Relative risk (95% CI) P value
Age (year) <50/≥50 0.661 (0.294-1.484) 0.315
Tumor size (cm) <4/≥4 1.341 (0.616-3.919) 0.460
Tumor differentiation Well-moderately/poor 0.836 (0.057-12.347) 0.896
FIGO stage Ib ~ IIa/IIb ~ IIIa 0.577 (0.038-8.702) 0.691
Lymph node metastasis Yes/no 0.032 (0.003-0.332) 0.004*
miR-205 Low/high 3.011 (1.312-6.910) 0.009*
95% CI: 95% confidence interval. *P < 0.05.
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and acts as a tumor suppressor or an oncogene depending
on cellular context [15]. In cervical cancer, miR-205 func-
tions as an oncogene, promoting proliferation and migra-
tion of cancer cells [13]. Our findings are suggestive of anFigure 4 Receiver operating characteristic (ROC) analysis was perform
expression level using area under the ROC curve (AUC) analysis. (A) S
cervical cancer from non-metastatic samples. (C) Separating well to moderoncogenic role for miR-205, with higher circulating ex-
pression of miR-205 in cervical cancer patients with a
lower survival rate. In this study, we identified that miR-
205 expression was significantly increased in cervical
cancer tissues compared with paracancerous tissues. Ined to determine the sensitivity and specificity of the miR-205
eparating stages Ib ~ IIa from stage IIb ~ IIIa. (B) Separating metastatic
ately differentiated from poorly differentiated.
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cancer patients had significantly elevated miR-205 levels
in their serum samples. This may be explained by miR-
205 being released from cervical cancer cells into the per-
ipheral blood, which is consistent with previous reports
[15]. An increase in serum miR-205 may create a cancer-
and metastasis-promoting environment. Thus, high levels
of miR-205 expression were correlated with poor tumor
differentiation, metastasis and increased tumor stage.
Tumor tissue miR-205 or serum miR-205 are associ-
ated with the development and prognosis of tumors
[15]. Lebanony et al. reported that miR-205 in tissue
samples is a highly accurate marker for distinguishing
squamous from nonsquamous non-small-cell lung car-
cinoma [16]. Moreover, the downregulation of miR-205
expression in colorectal cancer tissue could predict the
risk of lymph node metastasis [17]. Circulating miR-205
and let-7f together are diagnostic biomarkers for ovarian
cancer [18]. Aushev et al. revealed that the level of
plasma miR-205 strikingly decreased in patients after re-
moval of lung squamous cell carcinoma [19]. We also
assessed whether the miR-205 expression level could
function as a tumor marker to distinguish advanced
stage from early stage, metastatic cervical cancer from
non-metastatic samples and poorly differentiated tumors
from differentiated tumors. We found serum miR-205
was a valuable biomarker for cervical cancer patients.
Metastatic spread to regional lymph nodes is consid-
ered the most important prognostic factor in patients
with cervical cancer [20]. Currently, serum miRNAs
have been used to identify lymph node metastasis
(LNM) in cervical cancer patients. Zhao et al. reported
that miR-20a might be a potential biomarker for detect-
ing the lymph node status of cervical cancer patients,
with an AUC of 0.734, a sensitivity of 75% and a specifi-
city of 72.5% [21]. The comprehensive set of serum
miRNAs (miR-1246, miR-20a, miR-2392, miR-3147,
miR-3162-5p and miR-4484) have great potential to
serve as potential biomarkers for LNM in early-stage
squamous cell carcinoma, with an AUC of 0.992, a sensi-
tivity of 0.967 and a specificity of 0.950 [22]. In this
study, our analysis suggested that serum miR-205 might
be a novel biomarker for detecting LNM in cervical can-
cer patients. Our data also revealed that high levels of
serum miR-205 and LNM are independent predictors of
poor prognosis. Therefore, as a potential prognostic
biomarker in cervical cancer, the use of miR-205 might
improve patients’ risk stratification and guide their
treatment.
Conclusions
We observed that serum miR-205 levels could distin-
guish patients with cervical cancer from healthy con-
trols. The concentration of circulating miR-205 may bean important blood biomarker for cervical cancer screen-
ing and represents a potentially useful biomarker for
disease progression. The present data suggested that miR-
205 might be a valuable circulating marker for cervical
cancer with the potential to be translated into clinical
applications.Methods
Participants
Cervical cancer patients who underwent surgery between
January 2008 and August 2012 in Jiangsu Province hos-
pital on Integration of Chinese and Western Medicine
were enrolled in the present study. No patients had pre-
operative chemotherapy, radiotherapy or other treatment
history or other inflammatory diseases. The 60 enrolled
patients were aged from 34 to 71 years, with a median age
of 51 years. The pathological diagnosis of all 60 cervical
cancer patients was cervical squamous cell carcinoma.
The 60 control subjects were age-matched, healthy volun-
teers with no current or previous malignancy. All enrolled
individuals gave their informed consent, and the Ethical
and Scientific Committees of the hospital approved this
study. The degree of differentiation was well to moderately
differentiated in 27 cases, and poorly differentiated in 33
cases. Thirty-eight cases had lymph node metastases,
while 22 cases did not have lymph node metastases. The
clinical stage determined was according to the Inter-
national League of Gynecology and Obstetrics (FIGO,
2009). Twenty-six stage Ib ~ IIa cases were grouped as
early stage, and a total of 34 stage IIb ~ IIIa cases were
grouped as late stage. The clinicopathological information
of the patients was summarized in Table 1.Serum collection
Blood samples were collected in red tiger-top gel separ-
ator tubes (Thermo Fisher Scientific Inc., Waltham, MA,
USA) from patients or healthy donors. All samples were
processed within 2–5 h after collection as follows: the
serum was separated by centrifugation at 1,200 × g at 4°C
for 20 min and passed through a 13-mm serum filter
(Thermo Fisher Scientific Inc.). Serum was divided into al-
iquots and flash frozen at −80°C until total RNA isolation.Tissue samples
The non-tumor counterparts were obtained from a sec-
tion of the resected specimen at the farthest distance
from tumor (>2 cm from the tumor). Tumor and adja-
cent non-tumor samples were collected at the time of
the curative surgery. Resected specimens were routinely
processed for histopathological assessment. Each cervical
tissue sample (approximately 100 mg) was used for micro-
RNA measurement.
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chain reaction (qPCR)
The Trizol reagent (Invitrogen, Carlsbad, CA, USA) was
used to extract total RNA from tissue, according to the
manufacturer’s instructions. The miRNeasy Serum/
Plasma Kit (Qiagen, Valencia, CA, USA) was used to
purify RNA from serum samples according to the manu-
facture’s instructions. The yields of total RNA were 150–
300 ng per 400 μl of serum. For qPCR, miRNA-specific
TaqMan MicroRNA Assays (Applied Biosystems, Foster
City, CA, USA) for miR-16 (reference miR for serum),
U6 (reference miR for tissue) and miR-205 were per-
formed, as described by the manufacturer. Briefly,
100 ng of total RNA was reverse transcribed using
primers specific to each miRNA target, followed by real-
time PCR using an Applied Biosystems 7000 Sequence
Detection System.
The average expression levels of miR-205 were nor-
malized against miR-16 or U6 using the 2-ΔCt method.
Differences between the groups were presented as ΔCt,
indicating the difference between the Ct value of miR-
205 and the Ct value of miR-16 or U6. To ensure con-
sistent measurements throughout all assays, for each
PCR amplification reaction, three independent RNA
samples were loaded as internal controls to account for
any plate-to-plate variation, and the results from each
plate were normalized against internal normalization
controls.Statistical analyses
Statistical analyses were performed using statistical ana-
lysis software SPSS 13.0. Data were expressed as the
mean ± SD. Analysis of variance (ANOVA) was used to
determine the statistical differences among the groups.
The Kaplan-Meier method was used to estimate survival
rates. A multivariate analysis of the independent prog-
nostic factors was conducted using the Cox proportional
hazards model. A receiver operating characteristic
(ROC) curve was also constructed to evaluate the speci-
ficity and sensitivity of distinguishing advanced stage
from early stage, metastatic cervical cancer from non-
metastatic samples, and poorly differentiated tumors
from differentiated tumors by miR-205 expression levels.
A P value < 0.05 was deemed significant. A P value <
0.01 was deemed highly significant.
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